Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
D-Nature Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed between 2 distinct examiners, yet both are located within 1 distinct art unit. This indicates that while different individuals are reviewing the applications, the technical subject matter is consistent enough to be handled by a single administrative division. This centralization can lead to more uniform technical feedback across the portfolio.
ROSENTHAL, ANDREW S is the busiest examiner for the company, currently overseeing 1 pending office action. Since there are 2 pending office actions and 2 distinct examiners, each examiner is responsible for exactly half of the current pending workload. The focus on 1 distinct art unit suggests a concentrated technical strategy within the Biotechnology & Pharmaceuticals field. This profile shows that D-Nature Co. Ltd. is engaging with multiple examiners while maintaining a narrow technical scope for its 2 pending office actions, requiring consistency in arguments presented to the single art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSENTHAL, ANDREW S | 1 | 51.8% | +38.7% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034390 | COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY DISEASE AND AUTOIMMUNE DISEASES AND NON-ALCOHOLIC FATTY LIVER DISEASE, COMPRISING EXTRACT DERIVED FROM CENTIPEDA MINIMA | RODRIGUEZ, RAYNA B | 5d overdue |
| 18575351 | FUNCTIONAL COMPOSITION FOR ALOPECIA COMPRISING CENTIPEDA MINIMA-DERIVED EXTRACT | ROSENTHAL, ANDREW S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034390 | COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY DISEASE AND AUTOIMMUNE DISEASES AND NON-ALCOHOLIC FATTY LIVER DISEASE, COMPRISING EXTRACT DERIVED FROM CENTIPEDA MINIMA | RODRIGUEZ, RAYNA B | 5d overdue |
| 18575351 | FUNCTIONAL COMPOSITION FOR ALOPECIA COMPRISING CENTIPEDA MINIMA-DERIVED EXTRACT | ROSENTHAL, ANDREW S | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575351 | FUNCTIONAL COMPOSITION FOR ALOPECIA COMPRISING CENTIPEDA MINIMA-DERIVED EXTRACT | ROSENTHAL, ANDREW S | — | §103§112 | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18034390 | COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY DISEASE AND AUTOIMMUNE DISEASES AND NON-ALCOHOLIC FATTY LIVER DISEASE, COMPRISING EXTRACT DERIVED FROM CENTIPEDA MINIMA | RODRIGUEZ, RAYNA B | 1628 | §102§103§112Other | Non-Final OA | 5d overdue | Pending | Apr 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial